Oxaliplatin (Elplat® iv infusion solution) is a third-generation 1,2-DACH-platinum derivative. A number of international clinical trials have investigated the effects of this drug for each of its four indications. Building on the results of these earlier studies, much research has also been carried out in Japan in terms of developing and accumulating evidence on oxaliplatin. This report reviews the trajectory of its use over the last 10-years and considers its future potential.
|ジャーナル||Japanese Journal of Cancer and Chemotherapy|
|出版ステータス||出版済み - 6 2016|
All Science Journal Classification (ASJC) codes